NCT01575925 (POM Renal) is a Phase 1 clinical trial of 4 mg Oral POM + 40 mg Oral DEX in Multiple Myeloma, sponsored by Celgene.

Who is sponsoring NCT01575925?

NCT01575925 is sponsored by Celgene.

What drugs are being tested in NCT01575925?

Interventions in NCT01575925: 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX.

What condition does NCT01575925 study?

NCT01575925 studies Multiple Myeloma, Renal Impairment.

Is NCT01575925 still recruiting?

NCT01575925 is currently completed. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT01575925: POM Renal

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

Completed Phase 1 Last updated 4 November 2022

What this trial tests

Phase 1 trial testing 4 mg Oral POM + 40 mg Oral DEX in Multiple Myeloma in 25 participants. Completed in 7 August 2018.

Timeline

1 June 2012

Primary endpoint
7 August 2018

7 August 2018

Quick facts

Lead sponsor	Celgene
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	factorial
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 June 2012
Primary completion	7 August 2018
Estimated completion	7 August 2018
Sites	9 locations across Canada, United States

Drugs / interventions tested

4 mg Oral POM + 40 mg Oral DEX — full drug profile →
2 mg Oral POM + 40 mg Oral DEX — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →
Renal Impairment — all drugs for Renal Impairment →

Sponsor

Celgene — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma or Renal Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and impaired renal function.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.
Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, et al · · 2013 · cited 94× · PMID 24013664 · DOI 10.1038/bcj.2013.38
Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Celgene trials

Trials by the same sponsor.

NCT07242781 — A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult M · Phase 1 · recruiting
NCT06988488 — A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide · Phase 1, PHASE2 · recruiting
NCT06911502 — A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Ch · Phase 3 · recruiting
NCT06808984 — Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants W · Phase 2 · recruiting
NCT06782490 — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spastici · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01575925 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celgene
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01575925.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing